Novartis Fair Value
NO
The fair market value of NOVNEE.SW stock is 147.17 CHF. Relative to the market price of 99.82 CHF Novartis is undervalued by 47.5%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Novartis Valuation
Current NOVNEE.SW share ticker price is 99.82 CHF.
The fair value level of 147.17 CHF can be considered as an effective entry point for long-term investors to start investing in NOVNEE.SW stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 47% lower its fair value
Current price is 38% higher its minimum value
Current price is 104% lower its maximum value
Market price:
NOVNEE.SW stock is undervalued
It means the current price may concern as a Moderate Risk Entry Point
Novartis AG Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
23.27
2
Median P/E over 5 years
16.79
3
Minimum P/E over 5 years
7.12
4
Earning per share (last 12 months)
10.12 USD
Maximum value
1
x
4
=
204.03 CHF
Fair value
2
x
4
=
147.17 CHF
Minimum value
3
x
4
=
62.38 CHF
Novartis AG price metrics
3.69
Annual return (geometric mean)
18.87
Risk (standard deviation) of returns
β
0.71
Beta (volatility compared to market)